Merck & Co., Inc. (NYSE:MRK) Stock Price Target Cut by Royal Bank Of Canada

Key Points

• Royal Bank of Canada cut Merck’s price target from $150 to $145 while maintaining a “sector perform” rating, implying roughly 0.34% downside from the prior close.
• Analyst sentiment remains broadly positive, with 17 Buy ratings and 10 Holds; MarketBeat’s consensus view is “Moderate Buy” with an average target of $151.12.
• Merck shares traded near $145.50, while the company reported quarterly revenue of $16.61 billion—above expectations—and institutional investors owned 76.07% of outstanding shares.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) had its price target cut by research analysts at Royal Bank Of Canada from $150.00 to $145.00 in a research report issued on Monday, Benzinga reports. The firm currently has a "sector perform" rating on the stock. Royal Bank Of Canada's price target would indicate a potential downside of 0.34% from the company's previous close.

MRK has been the topic of a number of other reports. Leerink Partners boosted their price target on shares of Merck & Co., Inc. from $127.00 to $161.00 and gave the stock an "outperform" rating in a report on Wednesday, September 9th. Wall Street Zen lowered shares of Merck & Co., Inc. from a "buy" rating to a "hold" rating in a research report on Saturday, October 3rd. Rothschild & Co Redburn raised their price objective on shares of Merck & Co., Inc. from $140.00 to $145.00 and gave the stock a "buy" rating in a report on Monday, July 6th. Daiwa Securities Group upgraded shares of Merck & Co., Inc. from a "neutral" rating to an "outperform" rating and set a $143.00 price objective for the company in a report on Wednesday, August 12th. Finally, BMO Capital Markets lifted their price objective on shares of Merck & Co., Inc. from $142.00 to $170.00 and gave the stock an "outperform" rating in a research report on Thursday, August 20th. Seventeen investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $151.12.

Merck & Co., Inc. Stock Performance

MRK stock traded down $0.10 during midday trading on Monday, hitting $145.50. The company's stock had a trading volume of 932,888 shares, compared to its average volume of 10,605,065. The stock's 50-day moving average price is $143.90 and its 200 day moving average price is $128.37. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22. Merck & Co., Inc. has a 1 year low of $82.01 and a 1 year high of $156.92. The stock has a market cap of $358.97 billion, a price-to-earnings ratio of 116.45, a PEG ratio of 6.58 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%. The firm had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. During the same quarter in the prior year, the company earned $2.13 EPS. The business's revenue for the quarter was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, equities analysts forecast that Merck & Co., Inc. will post 2.66 EPS for the current year.

Insider Activity at Merck & Co., Inc.

In related news, EVP David Williams sold 52,847 shares of the company's stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the sale, the executive vice president directly owned 31,716 shares in the company, valued at approximately $4,084,069.32. This represents a 62.49% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Jennifer Zachary sold 80,315 shares of the firm's stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the completion of the transaction, the executive vice president directly owned 45,509 shares of the company's stock, valued at approximately $6,073,631.14. This trade represents a 63.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 228,238 shares of company stock worth $29,977,783 in the last ninety days. Insiders own 0.17% of the company's stock.

Institutional Investors Weigh In On Merck & Co., Inc.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Susquehanna Fundamental Investments LLC bought a new stake in shares of Merck & Co., Inc. during the 2nd quarter worth $11,470,000. Russell Investments Group Ltd. grew its position in Merck & Co., Inc. by 2.0% in the second quarter. Russell Investments Group Ltd. now owns 2,578,024 shares of the company's stock worth $331,931,000 after acquiring an additional 51,393 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in Merck & Co., Inc. by 7.0% in the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 6,184,340 shares of the company's stock worth $794,577,000 after acquiring an additional 402,011 shares in the last quarter. Talon Private Wealth LLC purchased a new position in Merck & Co., Inc. in the second quarter worth $995,000. Finally, Panagora Asset Management Inc. grew its position in Merck & Co., Inc. by 410.5% in the fourth quarter. Panagora Asset Management Inc. now owns 705,442 shares of the company's stock worth $74,255,000 after acquiring an additional 567,249 shares in the last quarter. Institutional investors own 76.07% of the company's stock.

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.